The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex's innovative FDA approved non-opioid therapies and pipeline candidate products.
The certification is an important prerequisite for health care and covers health and wellness as well as non-addictive pain management products.
Announcement advances the global expansion strategy for Scilex with plans for growing its presence in the Middle East and North Africa region with an initial focus on the UAE and Saudi Arabia.
PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, "Scilex" or "Company"), an innovative revenue generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it received Halal Certification of its commercial product ZTlido, indicating that ZTlido has undergone rigorous assessment to determine that it is permissible or acceptable in accordance with Islamic standards. The Halal certification was issued under the authority of Circle H International, Inc. ("Circle H") and offers the Company the opportunity to provide ZTlido to Islamic markets globally. This announcement supports the global expansion strategy for Scilex, which Scilex anticipates will include a presence in the Middle East and North Africa (MENA) region with an initial priority focus on the UAE and Saudi Arabia.
"Obtaining the broadly inclusive Halal Certification is a critical and important milestone in Scilex's plan to expand to potential Islamic markets for our innovative non-opioid non-addictive pain management therapeutic pipeline candidates and FDA approved products. With the global Muslim population representing over 25% of the world's population, according to Statista, this certification facilitates our ability to grow and expand in international markets," said Jaisim Shah, Chief Executive Officer and President of Scilex.
Circle H issued the Halal Certification based on the global standards promulgated by its esteemed Circle H Sharia Advisory Council (the "Council"). Circle H and the Council are recognized and supported by prominent governmental and non-governmental organizations and Islamic universities. Religious leaders drawn from these prominent institutions sit on or advise Circle H and the Council, for the development and support of its Halal standards.
该认证有可能在全球范围内打开进入伊斯兰市场的机会，扩大Scilex经美国食品药品管理局批准的创新非阿片类药物疗法和管道候选产品的潜在市场。
该认证是医疗保健的重要先决条件，涵盖健康和保健以及非成瘾性疼痛管理产品。
该公告推进了Scilex的全球扩张战略，计划扩大其在中东和北非地区的业务，最初的重点是阿联酋和沙特阿拉伯。
加利福尼亚州帕洛阿尔托，2024年3月15日（GLOBE NEWSWIRE）——专注于收购、开发和商业化用于治疗急慢性疼痛的非阿片类疼痛管理产品的创新创收公司Scilex控股公司（纳斯达克股票代码：SCLX，“Scilex” 或 “公司”）今天宣布，其商业产品ZTLido已获得清真认证，这表明ZTLido已获得清真认证经过严格评估，以确定根据伊斯兰标准是允许的还是可以接受的。清真认证是在Circle H International, Inc.（“Circle H”）的授权下颁发的，为公司提供了向全球伊斯兰市场提供ztLido的机会。该公告支持Scilex的全球扩张战略，Scilex预计该战略将包括在中东和北非（MENA）地区开展业务，最初的优先重点是阿联酋和沙特阿拉伯。
“获得广泛包容的清真认证是Scilex计划将我们的创新非阿片类非成瘾性疼痛管理候选药物和FDA批准的产品扩展到潜在的伊斯兰市场的关键而重要的里程碑。根据Statista的数据，全球穆斯林人口占世界人口的25％以上，该认证促进了我们在国际市场上增长和扩张的能力。” Scilex首席执行官兼总裁贾西姆·沙阿说。
Circle H根据其尊敬的Circle H伊斯兰教法咨询委员会（“理事会”）颁布的全球标准发布了清真认证。Circle H和理事会得到著名政府和非政府组织以及伊斯兰大学的认可和支持。来自这些知名机构的宗教领袖担任Circle H和理事会的成员，或向其提出建议，以制定和支持其清真标准。
